Did SURMOUNT-3 have a formal open-label extension phase?

No. The trial protocol included a 12-week lifestyle lead-in followed by 72 weeks of randomized, double-blind treatment. No open-label extension was pre-specified. Post-trial follow-up data from SURMOUNT-3 participants has not been published as of May 2025.

What happens when patients stop tirzepatide after losing weight?

SURMOUNT-4, a related trial with a randomized withdrawal design, showed that patients who switched from tirzepatide to placebo regained approximately 14% body weight over 52 weeks, losing roughly two-thirds of their treatment-phase benefit. This is consistent with discontinuation patterns seen across the GLP-1 receptor agonist class.

How does SURMOUNT-3 weight regain compare to semaglutide trials?

The STEP 1 extension study found that semaglutide-treated patients regained about two-thirds of lost weight within one year of stopping treatment. The SURMOUNT-4 withdrawal data for tirzepatide shows a similar proportional regain, suggesting this is a class-level phenomenon rather than specific to any single agent.

Were there any new safety signals in the later weeks of SURMOUNT-3?

Gastrointestinal side effects (nausea, diarrhea, vomiting) decreased over time as participants remained on stable doses. Gallbladder events occurred at low but higher rates with tirzepatide vs. placebo. No new unexpected safety signals emerged during the later treatment period that were not already identified during dose escalation.

Is there evidence that tirzepatide should be taken indefinitely for obesity?

Direct evidence from multi-year continuous tirzepatide use does not yet exist. The SURMOUNT-4 withdrawal data, the FDA label's lack of a specified treatment duration, and AACE guidelines recommending long-term pharmacotherapy all support indefinite use when the drug is effective and tolerated.

Did the lifestyle lead-in in SURMOUNT-3 affect long-term outcomes?

The lead-in selected for patients who could lose at least 5% body weight through diet alone. These responders then lost an additional 18.4% with tirzepatide, achieving 21.1% total loss. This total loss was comparable to SURMOUNT-1 (22.5% at the 15 mg dose), suggesting the lead-in did not meaningfully diminish tirzepatide's additional contribution.

Could patients reduce their tirzepatide dose after reaching their weight loss goal?

No SURMOUNT trial tested dose reduction as a maintenance strategy. This remains an open clinical question. Some prescribers attempt dose de-escalation in practice, but there is no randomized evidence supporting this approach without risking partial weight regain.

When will cardiovascular outcomes data for tirzepatide be available?

The SURPASS-CVOT trial is evaluating tirzepatide's effect on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. Results are expected around 2027. Until then, cardiovascular benefit has been demonstrated only for semaglutide (via the SELECT trial).

How much lean muscle mass do patients lose on tirzepatide?

Across the SURMOUNT program, approximately 25-30% of total weight lost was lean mass, consistent with expected ratios during caloric-deficit weight loss. SURMOUNT-3 did not include DXA body composition measurements. Whether resistance training during treatment preserves lean mass has not been studied in a controlled trial.

Does insurance cover long-term tirzepatide use for weight management?

Coverage varies widely by payer. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023 without a specified treatment endpoint. Many insurers impose prior authorization requirements, step therapy, or annual re-authorization, which can create gaps in treatment that may trigger weight regain.

SURMOUNT-3 Extension Data and What Happened After the Trial Ended

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for SURMOUNT-3 Extension Data and What Happened After the Trial Ended Image: HealthRX.com clinical image

At a glance

| Detail | Value | |---|---| | Trial | SURMOUNT-3 (NCT04657016) | | N | 579 randomized (after 706 entered lead-in) | | Intervention | Tirzepatide (max tolerated dose: 5, 10, or 15 mg weekly) | | Comparator | Placebo (both arms continued reduced-calorie diet + 150 min/week activity) | | Duration | 12-week intensive lifestyle lead-in, then 72-week randomized treatment | | Primary endpoint | Percent change in body weight from randomization to week 72 | | Key result | Tirzepatide arm lost an additional 18.4% from randomization; placebo lost 2.5% (total from screening: 21.1% vs 3.3%) | | Publication | Wadden et al., Nature Medicine 2023 |

Why Extension Data Matters for This Trial

SURMOUNT-3 asked a specific question that most obesity trials skip: if someone already responds to intensive lifestyle intervention, does adding a GLP-1/GIP dual agonist produce meaningful additional weight loss? The primary publication answered yes. Participants who had already lost at least 5% of body weight during a 12-week low-calorie diet phase went on to lose substantially more with tirzepatide.

But the trial ended at 72 weeks of randomized treatment. No pre-specified open-label extension was built into the SURMOUNT-3 protocol. That leaves a critical gap: what happens to patients who achieved 21% total weight loss once the drug stops?

The Discontinuation Problem: Lessons from SURMOUNT-4

SURMOUNT-3 itself does not include post-treatment follow-up data. The clearest window into what happens after stopping tirzepatide comes from SURMOUNT-4, published in JAMA in 2023. That trial used a different design: all 670 participants received open-label tirzepatide for 36 weeks, then those who achieved at least 5% weight loss were re-randomized to continue tirzepatide or switch to placebo for another 52 weeks.

The results were stark. Participants who continued tirzepatide lost an additional 5.5% body weight. Those switched to placebo regained 14.0% from their re-randomization weight. By week 88, the continued-treatment group had lost 21.4% total body weight. The placebo-switch group had regained roughly two-thirds of what they lost during the open-label phase.

Weight Trajectory Comparison: Continue vs. Stop

This framework maps the expected trajectory for a SURMOUNT-3-type patient (someone who responds to lifestyle, then adds tirzepatide) against the SURMOUNT-4 discontinuation curve.

| Timepoint | SURMOUNT-3 tirzepatide (continued treatment) | SURMOUNT-4 placebo switch (proxy for discontinuation) | |---|---|---| | End of lead-in / open-label | -5.0% (lifestyle lead-in) | -20.9% (36-week open-label tirzepatide) | | 6 months post-randomization | Approx. -12% additional | Regained ~8% from nadir | | 12-18 months post-randomization | -18.4% additional (total -21.1%) | Regained ~14% from nadir | | Net from baseline | -21.1% | Approx. -7% retained |

The pattern is consistent with semaglutide discontinuation data from the STEP 1 extension, where participants regained two-thirds of lost weight within one year of stopping treatment. Obesity pharmacotherapy, like antihypertensive therapy, appears to require continuation to maintain effect.

Regression to the Mean: A Methodological Consideration

SURMOUNT-3's design included an enrichment step that critics have flagged. The 12-week lifestyle lead-in selected for responders: only those who lost at least 5.0% body weight (127 of 706 screened participants were excluded or dropped out before randomization) entered the randomized phase. This raises a statistical concern about regression to the mean.

In practice, the placebo arm's modest additional 2.5% loss (on top of the lead-in loss) may partly reflect that some participants were at an unsustainable nadir from caloric restriction. The tirzepatide arm's 18.4% additional loss, though, is too large to explain away by regression effects alone. The treatment effect size (-15.9 percentage points vs. placebo) was comparable to SURMOUNT-1, which had no lifestyle lead-in enrichment.

Safety Signals Over the Full Treatment Period

The SURMOUNT-3 primary analysis reported safety across 84 total weeks of observation (12-week lead-in plus 72 weeks randomized). Several patterns deserve attention for clinicians thinking about long-term use.

Gastrointestinal Events

| Event | Tirzepatide (n=287) | Placebo (n=292) | |---|---|---| | Nausea | 24.6% | 8.2% | | Diarrhea | 16.4% | 8.6% | | Constipation | 11.5% | 4.1% | | Vomiting | 9.1% | 1.4% | | Discontinuation due to AEs | 6.3% | 1.4% |

GI side effects peaked during the dose-escalation phase (weeks 0-20 of randomized treatment) and generally attenuated. This is consistent with the broader SURMOUNT program and with GLP-1 receptor agonist class data reported in the tirzepatide FDA prescribing information.

Gallbladder Events

Across SURMOUNT-1 through SURMOUNT-4, cholelithiasis occurred at higher rates with tirzepatide than placebo. In SURMOUNT-3, gallbladder-related events were reported in 2.1% of tirzepatide-treated patients vs. 0.3% on placebo. Rapid weight loss is an established risk factor for gallstone formation, and the SURMOUNT-3 population lost weight at a rate exceeding 1% per week during the initial months. The American Gastroenterological Association has noted that weight loss exceeding 1.5 kg/week raises gallstone risk regardless of mechanism.

Lean Mass Loss

SURMOUNT-3 did not include DXA body composition substudies. Across the SURMOUNT program, the ratio of lean-to-fat mass loss has tracked at roughly 25-30% lean mass as a proportion of total weight lost, which is within the expected range for caloric-deficit weight loss. Whether concurrent high-protein diets or resistance training (neither mandated by protocol) modulated this ratio remains unknown from trial data.

What the Broader SURMOUNT Program Tells Us About Durability

The four completed SURMOUNT trials, taken together, paint a consistent picture.

| Trial | N | Duration | Max weight loss (tirzepatide) | Key design feature | |---|---|---|---|---| | SURMOUNT-1 | 2,539 | 72 wk | -22.5% (15 mg) | No enrichment, lifestyle counseling only | | SURMOUNT-2 | 938 | 72 wk | -14.7% (15 mg) | Type 2 diabetes population | | SURMOUNT-3 | 579 | 72 wk (after 12-wk lead-in) | -21.1% total | Lifestyle-responder enrichment | | SURMOUNT-4 | 670 | 88 wk total | -21.4% (continuers) | Randomized withdrawal design |

SURMOUNT-4 is the closest thing to extension data for the entire program. Its randomized withdrawal design proved that maintaining weight loss requires maintaining treatment. No SURMOUNT trial has published data beyond 88 weeks of tirzepatide exposure.

What We Still Do Not Know

Several questions remain open without formal extension studies:

Weight plateau timing. SURMOUNT-1 and SURMOUNT-3 both showed weight loss curves that had not fully plateaued at 72 weeks in the highest-dose arms. Whether patients would have lost additional weight with continued treatment beyond 72 weeks is unknown. The SELECT trial of semaglutide, which ran for a mean of 39.8 months, suggests GLP-1-class weight loss may continue slowly for 2+ years.

Cardiovascular outcomes. SURMOUNT-3 was not powered for cardiovascular events. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in 2027.

Dose optimization after initial loss. No SURMOUNT trial tested whether patients could step down to a lower tirzepatide dose after achieving target weight loss while maintaining their results. This is a common clinical question that current evidence cannot answer.

Combination with exercise. The SURMOUNT-3 protocol included 150 minutes per week of physical activity, but adherence was self-reported and not objectively measured. Whether structured resistance training during tirzepatide treatment preserves lean mass or enhances durability of weight loss after discontinuation has not been tested in a randomized design.

Clinical Translation: The Maintenance Imperative

The absence of SURMOUNT-3 extension data is itself informative. Eli Lilly's decision to design SURMOUNT-4 as a withdrawal study rather than extending SURMOUNT-3 reflects a strategic and scientific choice. The withdrawal design generates cleaner evidence for the regulatory and payer argument that obesity, like hypertension or hyperlipidemia, requires ongoing pharmacotherapy.

For prescribers, the combined SURMOUNT dataset supports three practical conclusions. First, lifestyle intervention before tirzepatide does not diminish the drug's additional effect. Second, stopping tirzepatide after achieving target weight will likely result in regaining most of the pharmacotherapy-attributable loss within 12 to 18 months. Third, the FDA label for tirzepatide (Zepbound) does not specify a treatment duration, consistent with the expectation of indefinite use.

The 2024 American Association of Clinical Endocrinology obesity guidelines explicitly state that anti-obesity medications should be continued long-term when effective, with periodic reassessment of benefit and risk. SURMOUNT-3, read alongside SURMOUNT-4, provides the evidence base for that recommendation in the tirzepatide-treated population.

Frequently asked questions

›

References

Wadden TA, et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial." Nature Medicine. 2023;29(11):2909-2918. PubMed
Aronne LJ, et al. "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial." JAMA. 2024;331(1):38-48. PubMed
Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387(4):327-340. PubMed
Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension." Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
Tirzepatide (Zepbound) prescribing information. U.S. FDA. Label
Garvey WT, et al. "American Association of Clinical Endocrinology consensus statement on obesity." Endocr Pract. 2024;30(5):S1-S68. PubMed